Drug Patents owned by Mylan Speciality Lp

1. Drug name - ASTEPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8518919 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof Nov, 2025

(3 years from now)

US9919050 MYLAN SPECIALITY LP Compositions comprising azelastine Nov, 2025

(3 years from now)

US8071073 MYLAN SPECIALITY LP Compositions comprising azelastine and methods of use thereof Jun, 2028

(5 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient

Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY SPRAY, METERED;NASAL Discontinued
0.2055MG/SPRAY SPRAY, METERED;NASAL Discontinued

2. Drug name - DYMISTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9259428 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Jun, 2023

(8 months from now)

US9901585 MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Jun, 2023

(8 months from now)

US8163723 MYLAN SPECIALITY LP Combination of azelastine and steroids Aug, 2023

(10 months from now)

US9259428

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and fluticasone for nasal administration Dec, 2023

(1 year, 2 months from now)

US8163723

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids Feb, 2024

(1 year, 4 months from now)

US8168620 MYLAN SPECIALITY LP Combination of azelastine and steroids Feb, 2026

(3 years from now)

US8168620

(Pediatric)

MYLAN SPECIALITY LP Combination of azelastine and steroids Aug, 2026

(3 years from now)

Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient

Treatment: Treatment of seasonal allergic rhinitis; Treatment of seasonal allergic rhinitis; treatment of allergic rhinitis, including seasonal allergic rhinitis; allergic rhinitis; treatment of symptoms of seasonal allergic rhinitis; relief of symptoms associated with seasonal allergic rhinitis

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.137MG/SPRAY;0.05MG/SPRAY SPRAY, METERED;NASAL Prescription

3. Drug name - EDLUAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia Apr, 2027

(4 years from now)

US9265720 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia Feb, 2031

(8 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;SUBLINGUAL Prescription
10MG TABLET;SUBLINGUAL Prescription

4. Drug name - EPI E Z PEN JR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8048035 MYLAN SPECIALITY LP Automatic injector with needle cover Sep, 2025

(2 years from now)

US7449012 MYLAN SPECIALITY LP Automatic injector Sep, 2025

(2 years from now)

US7794432 MYLAN SPECIALITY LP Automatic injector with kickback attenuation Sep, 2025

(2 years from now)

US9586010 MYLAN SPECIALITY LP Automatic injector with needle cover Sep, 2025

(2 years from now)

US8870827 MYLAN SPECIALITY LP Automatic injector Sep, 2025

(2 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.15MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Prescription
0.3MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Prescription

5. Drug name - ROWASA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7645801 MYLAN SPECIALITY LP Reduced irritant enema for treatment of inflammatory bowel disease (IBD)
Jul, 2027

(4 years from now)

EP2107870A2 MYLAN SPECIALITY LP Reduced Irritant Enema For The Treatment Of Inflammatory Bowel Disease (Ibd)
Jan, 2028

(5 years from now)

EP2107870A4 MYLAN SPECIALITY LP Improved Reduced Irritant Enema For The Treatment Of Inflammatory Bowel Disease (Ibd)
Jan, 2028

(5 years from now)

EP2107870B1 MYLAN SPECIALITY LP Reduced Irritant Enema For The Treatment Of Inflammatory Bowel Disease (Ibd)
Jan, 2028

(5 years from now)

Drugs and Companies using MESALAMINE ingredient

Treatment: NA

Dosage: ENEMA;RECTAL

More Information on Dosage
Strength Dosage Availability
4GM/60ML ENEMA;RECTAL Prescription

6. Drug name - TOBI PODHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9421166 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside Dec, 2022

(2 months from now)

US8715623 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycoside Dec, 2022

(2 months from now)

US7368102 MYLAN SPECIALITY LP Pulmonary delivery of aminoglycosides Dec, 2022

(2 months from now)

US7516741 MYLAN SPECIALITY LP Aerosolization apparatus with feedback mechanism Jan, 2024

(1 year, 3 months from now)

USRE47526 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield Apr, 2024

(1 year, 6 months from now)

US8069851 MYLAN SPECIALITY LP Aeorosolization apparatus with air inlet shield Sep, 2024

(1 year, 11 months from now)

US8664187 MYLAN SPECIALITY LP Methods of treatment of endobronchial infections Jun, 2025

(2 years from now)

US7559325 MYLAN SPECIALITY LP Aerosolization apparatus with air inlet shield Oct, 2025

(3 years from now)

US8869794 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncturing member Sep, 2028

(5 years from now)

US10207066 MYLAN SPECIALITY LP Aerosolization apparatus with capsule puncture alignment guide Nov, 2030

(8 years from now)

Drugs and Companies using TOBRAMYCIN ingredient

Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
28MG POWDER;INHALATION Prescription

availability in other generic markets.

Click on the highlighted region to filter.